Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current therapy of hepatitis C.

Robert J de Knegt1

  • 1Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. r.deknegt@erasmusmc.nl

Scandinavian Journal of Gastroenterology. Supplement
|June 20, 2006
PubMed
Summary

Hepatitis C virus (HCV) infection affects 170 million globally, causing significant liver disease. Recent advancements offer high treatment success rates, especially for genotypes 2 and 3, guiding antiviral therapy decisions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Liver stiffness dynamics in European populations (LiverScreen): a longitudinal, multicentre, prospective, population-based cohort study.

The lancet. Gastroenterology & hepatology·2026
Same author

Persistent loss of intrahepatic IFN-γ in HBV is linked to selective impairment of liver-resident CXCR6+NK cells despite long-term NUC therapy.

JHEP reports : innovation in hepatology·2026
Same author

Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study.

Lancet (London, England)·2026
Same author

Underuse of statins in MASLD despite population-based associations with lower liver stiffness.

JHEP reports : innovation in hepatology·2026
Same author

Diabetes Mellitus is a Risk Factor for Hepatic Encephalopathy Following Transjugular Intrahepatic Portosystemic Shunt.

Alimentary pharmacology & therapeutics·2025
Same author

Integrating Gut Microbiome and Metabolome to Gain Insight into Metabolic Dysfunction-Associated Steatotic Liver Disease.

Gastro hep advances·2025

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) infection is a global health issue affecting 170 million people.
  • While often asymptomatic, HCV can lead to severe liver conditions like cirrhosis and liver cancer.
  • Significant morbidity and mortality underscore the need for effective management strategies.

Purpose of the Study:

  • To provide an overview of current guidelines for antiviral therapy in Hepatitis C patients.
  • To discuss the efficacy of recent treatment advancements across different HCV genotypes.
  • To inform clinical decision-making regarding treatment initiation based on genotype and disease stage.

Main Methods:

  • Review of current literature and clinical guidelines on Hepatitis C treatment.
  • Analysis of sustained virological response rates for different antiviral therapies.
  • Evaluation of factors influencing treatment decisions, including HCV genotype and liver fibrosis.

Main Results:

  • High sustained virological response rates (>80%) achieved in genotypes 2 and 3.
  • Sustained virological response rates (>50%) achieved in genotype 1.
  • Treatment for genotypes 2 and 3 is recommended for all patients.
  • Treatment decisions for genotype 1 depend on liver biopsy findings and patient characteristics.

Conclusions:

  • Hepatitis C treatment has markedly improved, offering high cure rates.
  • Antiviral therapy should be considered for all patients with genotypes 2 and 3 HCV.
  • Personalized treatment approaches are necessary for genotype 1, considering fibrosis and patient factors.

Related Experiment Videos